| Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies (NCT05410041) | Beijing Boren Hospital | 2022-05-25 |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (NCT04771572) | Newave Pharmaceutical Inc | 2022-05-08 |
| CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia (NCT05727683) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2022-04-28 |
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia (NCT05326516) | Syndax Pharmaceuticals | 2022-03-09 |
| Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy (NCT05044039) | Washington University School of Medicine | 2022-02-28 |
| Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies (NCT04796675) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-04-10 |
| Genetic Polymorphisms in Drug Induced Neuropathy in Children With ALL (NCT05811910) | IRCCS Burlo Garofolo | 2021-03-30 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (NCT04629430) | University of Virginia | 2021-02-19 |
| Assessing the Ontogeny of P-glycoprotein Expression in Blood of Pediatric Leukemic Patients (NCT05021159) | Tanta University | 2020-03-01 |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors (NCT03934372) | Incyte Biosciences International Sàrl | 2020-01-29 |
| Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT (NCT03066466) | Loyola University | 2019-12-10 |
| Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (NCT03755414) | Washington University School of Medicine | 2019-09-04 |
| CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia (NCT04004637) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-08-25 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411) | Masonic Cancer Center, University of Minnesota | 2019-01-02 |
| Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia (NCT03840317) | Hebei Senlang Biotechnology Inc., Ltd. | 2019-01-02 |
| A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (NCT03555955) | Jazz Pharmaceuticals | 2018-11-20 |
| IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT (NCT03696537) | Naoyuki G. Saito, M.D., Ph.D. | 2018-08-29 |
| BESPONSA Injection 1 mg Special Investigation (NCT05923112) | Pfizer | 2018-07-02 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (NCT03448393) | National Cancer Institute (NCI) | 2018-03-26 |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies (NCT03263637) | AstraZeneca | 2017-10-24 |
| Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (NCT03104491) | Leland Metheny | 2017-07-31 |
| A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies (NCT03191773) | Second Affiliated Hospital of Guangzhou Medical University | 2017-06-30 |
| Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies (NCT03056339) | M.D. Anderson Cancer Center | 2017-06-21 |
| StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies (NCT02765997) | Masonic Cancer Center, University of Minnesota | 2017-04-01 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide (NCT03088709) | Loyola University | 2017-01-18 |
| Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia (NCT02914977) | Tara Lin | 2016-11-01 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma (NCT02819583) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-10-01 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma (NCT02851589) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-07-01 |
| Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation (NCT02750254) | Washington University School of Medicine | 2016-06-27 |
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies (NCT03076437) | Shenzhen Institute for Innovation and Translational Medicine | 2016-01-15 |
| BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT (NCT02670252) | Nanfang Hospital, Southern Medical University | 2016-01-01 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (NCT02593123) | Virginia Commonwealth University | 2015-11-04 |
| Reduced Intensity Conditioning Transplant Using Haploidentical Donors (NCT02581007) | Northside Hospital, Inc. | 2015-10-26 |
| Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies (NCT02410252) | Massachusetts General Hospital | 2015-05-01 |
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies (NCT02456350) | Shenzhen Second People's Hospital | 2015-04-01 |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (NCT02315612) | National Cancer Institute (NCI) | 2014-12-12 |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02129582) | Case Comprehensive Cancer Center | 2014-11-05 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant (NCT01930162) | Novartis Pharmaceuticals | 2014-10-07 |
| A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene (NCT02141828) | Epizyme, Inc. | 2014-05-01 |
| Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy (NCT02374333) | University of Pennsylvania | 2014-03-25 |
| Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (NCT01853631) | Baylor College of Medicine | 2014-02-01 |
| Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma (NCT02043587) | University of California, San Diego | 2014-01-01 |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (NCT01163201) | Masonic Cancer Center, University of Minnesota | 2014-01-01 |
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (NCT01634217) | Masonic Cancer Center, University of Minnesota | 2013-11-08 |
| Transfusional Iron Overload Among Leukemia Survivors (NCT01965171) | St. Jude Children's Research Hospital | 2013-10-18 |
| Human Placental-Derived Stem Cell Transplantation (NCT01586455) | New York Medical College | 2013-04-01 |
| Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies (NCT01745913) | Weill Medical College of Cornell University | 2012-10-26 |
| Double Cord Versus Haploidentical (BMT CTN 1101) (NCT01597778) | Medical College of Wisconsin | 2012-06-01 |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning (NCT01572662) | M.D. Anderson Cancer Center | 2012-04-11 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies (NCT01474681) | Novartis Pharmaceuticals | 2012-01-09 |
| Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation (NCT01491958) | Ohio State University Comprehensive Cancer Center | 2011-12-10 |
| Effect of Oral Supplementation With a Fibre Enriched Paediatric Sip Feed For Children With Acute Lymphocytic Leukemia (NCT01600781) | Children's Cancer Hospital Egypt 57357 | 2011-12-01 |
| Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match (NCT01500161) | Texas Oncology Cancer Center | 2011-11-01 |
| In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies (NCT01430390) | Memorial Sloan Kettering Cancer Center | 2011-09-01 |
| Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia (NCT01363297) | Pfizer | 2011-08-01 |
| Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (NCT01338987) | National Cancer Institute (NCI) | 2011-04-19 |
| Allo CART-19 Protocol (NCT01551043) | University of Pennsylvania | 2010-09-01 |
| Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) (NCT01167166) | Traws Pharma, Inc. | 2010-07-01 |
| Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia (NCT01162031) | Stanford University | 2010-06-01 |
| PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia (NCT01037556) | Proacta, Incorporated | 2010-01-01 |
| Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia (NCT01049113) | Traws Pharma, Inc. | 2009-11-01 |
| RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia (NCT00968253) | M.D. Anderson Cancer Center | 2009-11-01 |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy (NCT00990587) | University Health Network, Toronto | 2009-10-01 |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer (NCT00975975) | Indiana University | 2009-09-01 |
| Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy (NCT00963495) | University Health Network, Toronto | 2009-08-01 |
| CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (NCT00586391) | Baylor College of Medicine | 2009-02-01 |
| Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) (NCT00854646) | Traws Pharma, Inc. | 2008-10-01 |
| Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (NCT02007863) | University of Miami | 2008-08-01 |
| Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant (NCT00697684) | Beth Israel Deaconess Medical Center | 2008-06-01 |
| INCB018424 in Patients With Advanced Hematologic Malignancies (NCT00674479) | M.D. Anderson Cancer Center | 2008-05-12 |
| Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (NCT00852709) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2007-09-01 |
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors (NCT00701844) | University of North Carolina, Chapel Hill | 2007-07-01 |
| Stem Cell Transplantation for Patients With Cancers of the Blood (NCT00467961) | National Heart, Lung, and Blood Institute (NHLBI) | 2007-04-01 |
| Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML (NCT00430443) | Callisto Pharmaceuticals | 2007-02-01 |
| Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) (NCT00412360) | Medical College of Wisconsin | 2006-12-01 |
| Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia (NCT00773149) | Assistance Publique - Hôpitaux de Paris | 2006-10-01 |
| A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) (NCT00349596) | M.D. Anderson Cancer Center | 2006-07-01 |
| Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia (NCT00352677) | CytRx | 2006-07-01 |
| Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia (NCT00271063) | Callisto Pharmaceuticals | 2005-10-01 |
| Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases (NCT00309842) | Masonic Cancer Center, University of Minnesota | 2005-07-28 |
| HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies (NCT00145626) | St. Jude Children's Research Hospital | 2004-05-01 |
| Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor (NCT00304720) | Colorado Blood Cancer Institute | 2004-03-01 |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers (NCT00089596) | ViaCell | 2004-03-01 |
| Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology (NCT01310946) | King Faisal Specialist Hospital & Research Center | 2003-06-01 |
| Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier" (NCT00155844) | National Taiwan University Hospital | 2003-02-01 |
| Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT (NCT00516152) | University of California, San Francisco | 2002-11-01 |
| Investigation of Clofarabine in Acute Leukemias (NCT00098033) | University of Texas | 2002-09-01 |
| Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. (NCT00149136) | Hospices Civils de Lyon | 2002-08-01 |
| Nonmyeloablative Allogeneic Transplant (NCT01272817) | Scripps Health | 2001-10-01 |
| The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen (NCT01890486) | Wake Forest University Health Sciences | 2001-05-21 |
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant (NCT00571662) | University of Nebraska | 2000-12-08 |
| A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia (NCT00001689) | National Cancer Institute (NCI) | 1998-01-01 |
| Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia (NCT00251368) | Dana-Farber Cancer Institute | 1995-01-01 |